1Siegel R, Ward E, Brawley 0, et al. Cancer statistics, 2011: Theimpact of eliminating socioeconomic and racial disparities on pre-mature cancer deaths [J].CA Cancer J Clin,2011,61(4):212-236.
2Tannock IF, Osoba D, Stockier MR, et al. Chemotherapy with mito-xantrone plus prednisone or prednisone alone for symptomatic hor-mone-resistant prostate cancer: A Canadian randomized trial withpalliative end points [J].J Clin Oncol, 1996,14(6): 1756-1764.
3Berthold DR, Pond GR, de Wit R, et al. Survival and PSA re-sponse of patients in the TAX 327 study who crossed over to re-ceive docetaxel after mitoxantrone or vice versa [J].Ann Oncol,2008,19(10):1749-1753.
4Kelly WK, Halabi S, Carducci M, et al. Randomized, dou-ble-blind, placebo-controlled phase III trial comparing docetaxeland prednisone with or without bevacizumab in men with metastat-ic castration-resistant prostate cancer: CALGB 90401 [J].J Clin0ncol.2012,30(13):1534-1540.
5Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estra-mustine compared with mitoxantrone and prednisone for advancedrefractory prostate cancer [J].N Engl J Med,2004,351(15):1513-1520.
6Sternberg CN,Petrylak DP, Sartor O, et al. Multinational, dou-ble-blind, phase III study of prednisone and either satraplatin orplacebo in patients with castrate-refractory prostate cancer pro-gressing after prior chemotherapy: The SPARC trial [J].J Clin On-col,2009,27(32):5431-5438.
7De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazi-taxel or mitoxantrone for metastatic castration-resistant prostatecancer progressing after docetaxel treatment: A randomizedopen-label trial [J].Lancet,2010,376(9747): 1147-1154.
8Reid AH, Attard G, Danila DC, et al. Significant and sustained an-titumor activity in post-docetaxel, castration-resistant prostate can-cer with the CYP17 inhibitor abiraterone acetate [J].J Clin Oncol,2010,28(9):1489-1495.
9De Bono JS, Logothetis CJ, Molina A,et al. Abiraterone and in-creased survival in metastatic prostate cancer [J].N Engl J Med,2011,364(21):1995-2005.
10KantoffPW, Higano CS, Shore ND, et al. Sipuleucel-T immuno-therapy for castration-resistant prostate cancer [J].N Engl J Med,2010,363(5): 411-422.
二级参考文献16
1Crawford E D, Eisenberger M A, Mcleod D G, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma[J]. New Engl J Med, 1989 321:419.
2Mcleod D. Hormonal therapy in the treatment of carcinoma of the prostate[J].Cancer, 1995,75 : 1914 - 1919.
3Chapelon J Y, Margolari J, Vernier F, et al. In vivo effects of hige-intensity ultrasound on prostatic adeno- carcinoma Dunning R3327[J]. Cancer Res, 1992, 52: 6353-6357.
4Thuroff S, Chaussy C. Therapy of local prostatic carcinoma with high-intensity focused ultrasound (HIFU) [M]. outcome and side effects. Urologe A, 2001. 40191 -40194.
5Chaussv C, Thuroff S. Results and side effects of high- intensity focused ultrasound in localized prostate cancer [J]. J Endourol, 2001, 15:437-440.
6Holm HH. The history of interstitial brachytherapy of prostatic cancer [ J ]. Semin Surg Oncol, 1997,13 (6) : 431 - 437.
7Holm HH, Stroyer I, Hansen H, et al. Ultrasonically guided percutaneous interstitial implantation of iodine-125 seeds in cancer therapy [ J ]. Br J Radiol, 1981,54 ( 644 ) : 665 - 670.
8Kent EC, Hussain MHA. The patient with hormone refractory prostate cancer: determining who, when and how to treat [ J ]. Urology, 2003,62 ( Suppl 1 ) : 134 - 140.
9Nath R, Anderson LL, Luxton G, et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 [ J ]. Med Phys, 1995,22 (2) :209 - 233.
10Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standard and future prospects [J]. J Urol,1998,160(4):1220- 1229.
4Jemal A,Bray F,Center M M,et al. Global cancer statistics[J]. CA Cancer J Clin, 2011,61 (2) : 261-263.
5Jemal A,Siegel R,Xu J,et al. Cancer statistics,2010[J]. CA Cancer J Clin, 2010,60(5) : 277-300.
6Meleod D, Zinner N, Tomerra K, et al. A phase 3, muticenter, open- lable,randominzed study of abarelix versus leuprolide acetate in men with prostate cancer[J]. Urology, 2011, 58(5): 756-761.
10Kubo T, Sugita T, Scimose S, et al. Targeted systemic chemotherapy using megnetie liposomes with ineroporated adriamycin for osteosar coma in ham sters[J]. Int Oncol, 2001, 18(1): 121.
